Researchers strive to optimize preclinical insights while minimizing animal use, often turning to dogs and NHPs due to their size and physiological relevance. However, navigating through study complexities and physiological discrepancies, particularly in macaques and beagles, presents unique challenges. Here are key considerations:
1.Pre-Trial Data:
Regular pre-trial data collections aid in tracking changes over time, facilitating adaptation to procedures, and identifying abnormal health conditions. Parameters such as red blood cell (RBC) count, neutrophil counts, and liver enzyme activity serve as vital indicators. Excluding animals with abnormal parameters enhances data interpretation.
2.Trial Design Variables:
Blood sampling for pharmacokinetics/pharmacodynamics (PK/PD) studies is common but may impact parameters like RBC count and muscle enzyme activity. Maintaining standardized conditions during sampling is imperative. Variables such as animal age, fasting, and route of administration also influence data interpretation.
3.Red Blood Cells:
Dogs and macaques have longer RBC lifespans compared to rodents. Regional variations in crab-eating macaque RBCs affect counts, while factors like splenic activity and mean corpuscular hemoglobin concentration (MCHC) levels influence data interpretation and exclusion criteria.
4.White Blood Cells:
Neutrophils and lymphocytes dominate peripheral blood white cell counts across species, but proportions vary significantly. Dogs typically exhibit higher neutrophil counts (50-75% of WBCs) compared to macaques (25-50%), which still exceed rodents. Stronger inflammation responses mediated by neutrophils in dogs and macaques pose challenges in interpreting changes related to test substances due to limited animal numbers and confounding factors like stress-induced leukocytosis. Transient lymphocytosis in healthy macaques may indicate viral infections in most cases.
5.Coagulation:
Dogs have the shortest prothrombin time (PT), demanding high sensitivity in coagulation analyzers. Some beagles lack coagulation factor VII, slightly extending PT, detectable in pre-trial data. Macaque activated partial thromboplastin time (APTT) range can double with different reagent batches, complicating interpretation. Deviations from standard procedures warrant attention.
http://www.prisysbiotech.com/nhp-pharmacology/coagulation-hemostasis-nonhuman-primates.html
6.Liver Function:
Alanine aminotransferase (ALT) remains pivotal for detecting hepatocyte damage. Dogs exhibit narrow ALT ranges (25-40 IU/L), allowing sensitive detection of changes induced by test substances. Macaque ALT ranges are broader, influenced by age and often subclinical hepatitis A infection. Transient ALT elevations post-infection may complicate interpretation. Alkaline phosphatase (ALP) is sensitive in dogs but not macaques for bile issues. Gamma-glutamyl transferase (γ-GT) is more sensitive and specific in macaques. Total bilirubin is unreliable in both species.
7.Kidney Function:
Urea and creatinine levels in young beagles are narrow, making them sensitive indicators of renal effects in preclinical studies. However, variations in macaques are wider. Urinalysis provides limited insights due to challenges in sample collection from uncooperative animals. Improved techniques like catheterization may enhance sample quality.
8.Muscle Injury:
Assessing muscle damage is easier in dogs than in macaques. Incidental injuries from procedures are common in macaques, reflected in changes in creatine kinase (CK) activity. Cardiac troponins are better markers for myocardial injury in both species, surpassing isoenzymes.
9.Carbohydrates, Proteins, and Lipids:
Blood glucose in macaques is typically lower but can increase due to stress during collection. High levels may indicate diabetes and warrant reevaluation. Macaques have higher total protein and globulin concentrations, fluctuating widely. Elevated globulin may suggest inflammation or infection.
10.Inorganic Substances and Electrolytes:
Calcium and phosphate differences in macaques exceed those in dogs. Electrolyte concentrations in macaques can vary significantly, with high levels occasionally observed. Overall, these parameters provide valuable insights into organ function and potential effects of test substances in preclinical studies.
Conclusion:
Interpreting clinical pathology data in studies involving dogs and macaques is influenced by various factors, including small sample sizes, individual animal variability, and other study-related factors. While population differences remain important, individual animal variations may have greater indicative significance. Proper interpretation of clinical pathology data requires thorough evaluation of all available data, understanding species characteristics, and considering the impact of various study design variables.
